Novo says diabetes drug IDegLira shows superior blood sugar control
COPENHAGEN Dec 3 (Reuters) - Denmark's Novo Nordisk said on Tuesday that a phase 3 trial of its diabetes drug IDegLira showed better control of blood sugar levels than its own long-acting insulin Tresiba.
IDegLira is a combination of Tresiba and Victoza, Novo's glucagon-like peptide-1 (GLP-1) diabetes drug. GLP-1 drugs work by stimulating the release of insulin when blood sugar levels become too low.
Novo, the world's biggest insulin producer, said in a separate press release that its combination diabetes drug Ryzodeg showed improved glycaemic control, with lower rates of hypoglycaemia than biphasic insulin aspart 30.
Sales of diabetes drugs were worth $42.4 billion worldwide in 2012, according to healthcare information company IMS Health. France's Sanofi and U.S. company Eli Lilly are Novo's main competitors in the market.
- Female Yahoo executive sued for sexual harassment
- Gaza toll passes 100; Israel to counter rockets 'with all power' |
- Ukraine scrambles fighter jets above rebel positions as missile attack resumes
- U.S. Navy maintains grounding order for F-35 fighter jets
- Ebola deaths surge in Sierra Leone and Liberia: WHO